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Background: This review evaluated the safety and efﬁ  cacy of etanercept in patients with ankylosing spondylitis (AS).
Methods: Of 59 patients with AS, this study reviewed 11 patients who were refractory to conventional therapy and treated with 
etanercept from September 2005 to January 2008. The mean follow-up duration was 13.6 months. The general improvement 
was evaluated by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and adverse effects, complications and 
inﬂ  ammatory markers were also assessed.
Results: The mean BASDAI decreased from 7.1 ± 1.6 before treatment to 4.2 ± 1.8 at 3 months after the etanercept treatment (p = 
0.001). The mean erythrocyte sedimentation rate and C-reactive protein were decreased signiﬁ  cantly by the etanercept treatment. 
The greatest improvement in symptoms was enthesitis, followed by skin involvement and morning stiffness. There was a 
signiﬁ  cant difference in the improvement in BASDAI along with the follow up duration (p = 0.04). A serious infection was observed 
as a complication in 1 case.
Conclusions: These results suggest that etanercept can induce signiﬁ  cant improvement in most patients with less damage. A 
trial of tumor necrosis factor inhibition is indicated in all AS patients who do not achieve adequate disease control with disease-
modifying antirheumatic drugs, such as methotrexate, leﬂ  unomide etc. The patients treated with etanercept should be educated 
about the possibility of infection and monitored closely.
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progressively before the age of 40, lasts for more than 
3 months, is associated with morning stiffness, and 
improves with exercise. Although the factors affecting 
the progress of AS have not been established, advanced 
AS can be associated with severe functional impairment, 
work disability, and a compromised quality of life.
1) 
Therefore, the treatment efforts should be focused on 
reducing the level of pain, stiff  ness and fatigue as well as 
maintaining good posture and physical, psychological, 
and social functions.
1) The treatment methods for AS 
are strongly dependent on the use of non-steroidal anti-
infl  ammatory drugs (NSAIDs), cyclooxygenase-2 (COX-
2) inhibitors, and oral steroids. They are effective in 
improving symptoms but are ineffective in retarding the 
progress of the disease. In addition, disease-modifying 
antirheumatic drugs (DMARDs), such as sulfasalazine or 
methotrexate, which are used in patients unresponsive to 
NSAIDs, reduce the peripheral symptoms albeit limitedly 
but are less eff  ective in the treatment of the symptoms of 
Ankylosing spondylitis (AS), seronegative spondylo-
arthritis involving primarily the spine and the sacroiliac 
joint, is a chronic inflammatory rheumatoid disease 
causing more than 3 months of constant pain.
1-4) It is 
found in 0.5-1% of the population and is 2-3 times more 
prevalent in males than females.
5) AS is associated with 
inflammation of the axial skeleton, peripheral arthritis, 
enthesitis and mucocutaneous lesions.
3,5) The most 
common early symp  toms include minor and obscure 
lumbar pain and morning stiff  ness lasting for more than 3 
hours. Such infl  ammatory back pain can be diff  erentiated 
from mechanical back pain in that the former increases 29
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the axial skeleton.
5) Recently, the Assessment in the AS 
international working group (ASAS) and the European 
League Against Rheumatism (EULAR) recommended 
anti-tumor necrosis factor (TNF)-α treatments in AS 
patients unresponsive to other drugs. There are also 
reports showing the cost-effectiveness of anti-TNF-α 
therapies: the treatment is expensive but results in rapid 
and constant improvement. On the other hand, the US 
FDA recommended the careful use of etanercept to avoid 
serious infections. Domestically, etanercept has been used 
in some patients with AS since 2003. However, its effi   cacy 
and safety have not been addressed. Th   is study examined 
the effi   cacy, use, and safety of etanercept in patients with 
ankylosing spondylitis. 
METHODS 
Between September 2005 and February 2008, 59 patients 
were diagnosed with AS and met the modifi  ed New York 
criteria at our institution. Of these patients, 11 patients, 
who were unresponsive to conventional drug treatments, 
were enrolled in this study (Table 1). They had serious 
active AS showing less than satisfactory changes aft  er more 
than 3 months use of 2 or more NSAIDs or DMARDs or 
had side eff  ects requiring discontinuation of therapy.
Etanercept is a fusion protein consisting of two p75 
TNF receptor extracellular domains and the Fc portion 
of human immunoglobin G1 (IgG1). It binds TNF-α se-
lec  tively, and blocks the interaction of TNF-α with its 
cell sur  face receptors. It was approved by the US FDA in 
November 1998 as the fi  rst biological agent for the treat-
ment of rheumatoid arthritis. In Korea, it has been used to 
treat rheumatoid arthritis from December 2003 since its 
approval by the Korean FDA in October 2003. As of July 
1 2007, it can be prescribed for an additional 6 months if 
the Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) score is reduced to 50% of the pre-treatment 
value or by more than 2 units at the 3rd month. Th  ereaft  er, 
it can be used for up to 24 months if the value obtained at 
the 3rd month is maintained in the evaluation performed 
every 6 months. 
In this study, 25 mg of etanercept (Enbrel®; Im-
munex, Seattle, WA, USA) was injected subcutaneously 
into the patients twice a week with a 72 to 96 hour inter-
val. Th   e patient’s data, including gender, age, duration of 
illness, main complaints, extraarticular symptoms, dosage 
and duration of treatment with the anti-TNF agent, 
and use of the conventional agents for the treatment of 
ankylosing spondylitis, was collected retrospectively from 
the medical records and by a telephone interview. All the 
patients were examined for any history of pneumonia 
prior to the injection and underwent sputum Acid Fast 
Bacilli (AFB) Stain 3 times, a chest X-ray, a hepatitis B 
virus test (HBsAg, HBsAb, HBe Ag, HBeAb, HBV DNA), 
an alanine aminotransferase (ALT) test, and an aspartate 
aminotransferase (AST) test. The presence of HLA-B27 
was determined and the creatinine, bilirubin, erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), and 
Anti-Nuclear Antibody (ANA) levels were measured aft  er 
each injection. After the etanercept injection, the occur-
rence of side effects and complications were ex  amined. 
Th   e BASDAI was used to assess the level of improvement. 
Statistical analysis was performed using the SPSS ver. 
12.0 (SPSS Inc., Chicago, IL, USA). A paired t-test was 
used to compare the ESR and CRP levels before and 
aft  er the etanercept injection, and the Kruskal-Wallis test 
and Mann-Whitney test were employed to compare the 
BASDAI, ESR, and CRP levels according to the illness 
duration. A p-value of < 0.05 was considered signifi  cant. 
RESULTS
Epidemiological Characteristics and Clinical Patterns 
(Table 1)
Th   e medical records of the 11 patients (9 males and 2 fe-
males) with AS were examined. The mean age was 33.3 
years (range, 19 to 52 years). Th   e mean duration from the 
Characteristics Values (N = 11)*
Age 33.3
Sex
    Male   9 (92)
    Female   2 (18)
Duration of AS    7.2
Prior DMARDs used   11 (100)
DMARDs use at baseline   11 (100)
    Methotrexate 10 (91)
    Sulfasalazine 10 (91)
    Hydroxychloroquine   2 (18)
    Oral Corticosteroid   11 (100)
Values are presented as number (%) or mean yr.
DMARD: Disease-modifying antirheumatic drugs.
*Patients who received etanercept.
  Table 1. Characteristics of the Patients with Ankylosing Spondylitis 
(AS)30
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diagnosis of AS to the etanercept treatment was 7.2 years 
(range, 0.5 to 18 years). The mean follow-up period was 
13.6 months (range, 4 to 30 months).
Th   e DMARDs used before the etanercept treatment 
included methotrexate in 10 (91%) cases, sulfasalazine in 
10 (91%) cases, oral corticosteroid in 11 (100%) cases, and 
hydroxychloroquine in 2 (18%) cases. Etanercept was used 
for 12, 36, and 72 weeks in 9, 1, and 1 patient, respectively. 
All the patients tested positive for HLA-B27. The 
main complaints at the initial examination were back 
pain, motor dysfunction and morning stiffness of the 
spine. Other symptoms included hip joint pain in 2 cases, 
shoulder pain in 1 case, and knee joint pain in 1 case. 
Uveitis was the only extraarticular symptom found in 1 
case. Th   ere were 3 cases of extra-axial arthritis, including 
2 cases of coxarthritis and 1 case of gonarthritis. Of 
the patients, a 22-year-old male with morning stiffness 
of the lumbar spine and pain in the left hip caused by 
ankylosing arthritis had been treated with NSAIDs and 
DMARDs for 1 year. However, the continuing symptoms 
required total hip arthroplasty and the use of etanercept 
at the 4th postoperative year. A 19-year old male with 
pain in his right knee had been treated with NSAIDs and 
DMARDs for 1 year. However, arthroscopic debridement 
and synovectomy performed twice due to constant pain 
and swelling, and etanercept was administered at the 2nd 
postoperative year. 
With regard to the underlying conditions, cardio-
vascular disorders associated with blood pressure and 
arrhythmia were encountered in 2 cases, anemia in 1 case, 
diabetes in 1 case, pneumonia in 1 case, and a tumor in 
1 case. A history of pneumonia was found in 1 of the 11 
patients, who had achieved full recovery with 1-year use 
of antituberculosis drug 2 years before the administration 
of etanercept. The anti-TNF-α therapy was started when 
there were no signs of active pneumonia according to plain 
radiography and a sputum examination. In 1 case, a tumor 
resection was required before the use of etanercept due 
to multiple osteochondroma, and no relapse or neoplasm 
was encountered during the therapy. 
Changes in the BASDAI Before and Aft  er the Et  anercept 
Treatment
Before the etanercept treatment, the mean BASDAI was 
7.1 ± 1.6 (fatigue, 7.6 ± 1.5; symptoms of the axial skel-
eton, 7.7 ± 1.6; peripheral arthritis, 6 ± 3.6; enthesitis or 
skin involvement, 7.1 ± 2.6; level of morning stiffness, 8 
± 2; duration of morning stiffness, 5.3 ± 3.7). The mean 
BASDAI decreased by 45% to 4.2 ± 1.8 at the 3rd month 
of the etanercept treatment. Fatigue was reduced by 30% 
to 5.2 ± 1.5 on average, the symptoms of the axial skeleton 
improved by 36% to 4.6 ± 1.5, and the level of peripheral 
arthritis decreased by 43% to 3.2 ± 3.5. The symptoms 
associated with enthesitis or skin involvement were 
reduced by 49% to 3.3 ± 2.6. Th   e mean level of morning 
stiffness decreased by 40% to 4.9 ± 2 and the mean 
duration of morning stiff  ness was shortened by 51% to 3.3 
± 2.6. Enthesitis, skin involvement, and morning stiff  ness 
showed most improvement since the use of etanercept (Fig. 
1). Th   e mean BASDAI was decreased 45% from 7.1 ± 1.6 
to 4.2 ± 1.8 using etanercept (p = 0.001). 
In 3 patients with a more than 8 year duration of 
Fig. 1. Mean Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) scores of the patients who received etanercept at wk 0, 12.   
The mean BASDAI scores decreased from the baseline (p = 0.001).
Fig. 2. Disease activity indicator (erythrocyte sedimentation rate [ESR]); 
ESR at 0, 3, 6, 12 mo decreased signiﬁ  cantly (p = 0.051).31
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illness, the mean BASDAI decreased from 6.8 ± 0.3 to 4.1 
± 2.7. Th   e mean BASDAI in 5 patients with a 3 to 8 year 
and a ≤ 3 year duration of illness decreased from 7.5 ± 1.8 
to 4.6 ± 1.9 and from 6.6 ± 2.2 to 3.4 ± 1.5, respectively. 
With regard to the changes in the BASDAI between 
before the injection and at 3rd months since the injection, 
marginal statistical signifi  cant was identifi  ed in those with 
a 3-8 year duration of illness (p = 0.04), while no statistical 
signifi  cance was found in those with an illness duration ≥ 
8 years (p = 0.376) or ≤ 3 years (p = 0.513).
Changes in the ESR and CRP between Before and Aft  er 
the Etanercept Treatment 
Th   e ESR of the 11 patients decreased from 44.6 ± 34.1 at 
the time of injection to 19.6 ± 14.1, 20.8 ± 21.9, and 15.8 ± 
24.5 at 3, 6, and 12 months since the injection, respectively 
(Fig. 2). The CRP also fell from 4.1 ± 3.8 at the time of 
injection, to 1.3 ± 2.3, 1.7 ± 2.9, and 1.8 ± 4.6 at 3, 6, and 
12 months since the injection, respectively (Fig. 3). The 
p-value for the changes in ESR was 0.051, which is slightly 
higher than 0.05, but still showing marginal signifi  cance. 
On the other hand, the p-value for the CRP changes was 
0.045, which showed a signifi  cant decrease. 
In the 3 patients with a ≥ 8 year duration of illness, 
the mean ESR decreased from 43.3 ± 20.8 to 24.3 ± 22, 15 
± 11.4, 15 ± 11.4 at 3, 6, and 12 months since the injection, 
respectively. In the 5 patients with a 3-8 year duration of 
illness, the mean ESR was 41.8 ± 28.3 before the injection, 
and 22.4 ± 7.7, 21.3 ± 11.6, and 22.2 ± 35.9 at 3rd, 6th, 
and 12th months since the injection, respectively. In the 3 
patients with ≤ 3 year duration of illness, the mean ESR fell 
from 50.7 ± 60.7 before the injection to 10.3 ± 14.4, 26 ± 
41.6, and 6 ± 6.9 at 3, 6, and 12 months since the injection, 
respectively. When the ESR levels before the injection 
and at 12 months since the injection were compared in 
each patient group categorized according to the illness 
duration, there was no signifi  cant diff  erence between the 
three groups: ≥ 8 years of duration of illness (p = 0.184), 
3-8 years of duration of illness (p = 0.249), and ≤ 3 years of 
duration of illness (p = 0.121). 
The mean CRP decreased from 6 ± 5.1 before the 
injection to 2.6 ± 4.4, 0.1 ± 0, and 0.7 ± 1.1 at 3, 6, and 
12 months since the injection, respectively, in 3 patients 
with ≥ 8 years of duration of illness; from 4.2 ± 4 before 
the injection to 0.7 ± 0.6, 1.5 ± 2, and 3.4 ± 6.8 at 3, 6, and 
12 months since the injection, respectively, in 5 patients 
with 3-8 years of duration of illness; and from 2.2 ± 1.9 
before the injection to 0.9 ± 1.4, 2.9 ± 4.9, and 0.1 ± 0 at 
3, 6, and 12 months since the injection, respectively, in 3 
patients with ≤ 3 years of duration of illness. When the 
CRP levels before the injection and at the 12th month 
since the injection were compared in each patient group 
categorized according to the duration of illness, there was 
no statistical diff  erence between the three groups; patients 
with ≥ 8 years of duration of illness (p = 0.121), 3-8 years 
of duration of illness (p = 0.389), and ≤ 3 years of duration 
of illness (p = 0.121). 
Complications Following the Etanercept Treatment 
(Table 2)
A case of pruritus at the injection site developed during 
the etanercept treatment and a case of superfi  cial infection 
at the injection site was encountered aft  er the treatment. 
In one 22-year-old male patient who had undergone 
total hip arthroplasty due to ankylosis of the left hip 4 
years before the etanercept treatment, flare and burning 
sensation appeared in the left inguinal area after the 
injection. Th   ree weeks later, the injection was stopped and 
drainage and biopsy of the infected area were performed 
urgently. He has been followed since because revision total 
Fig. 3. Disease activity indicator C-reactive protein (CRP); CRP at 0, 3, 6, 
12 mo decreased signiﬁ  cantly (p = 0.045).
Event Values (N = 11)*
Infection 1 (9)
Injection site reaction 1 (9)
Upper respiratory tract infection 1 (9)
Tuberculosis 0 (0)
Elevation of ALT, AST  1 (9)
Values are presented as number (%).
ALT: Alanine aminotransferase, AST: Aspartate aminotransferase.
*Patients who received etanercept.
  Table 2. Incidence of Adverse Events32
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hip arthroplasty might be necessary. In 1 case, an elevation 
of the AST/ALT ratio was noted temporarily after the 
injection, but it was minor and did not develop into ful-
minant hepatitis or liver cirrhosis. During treatment, an 
upper respiratory infection was identified in 1 patient 
in whom the treatment was stopped because the signs 
of pneumonia were identified from a chest X-ray taken 
at the 3rd month since the injection. Etanercept was re-
administered 1 month later when pneumonia was ruled 
with chest X-ray showing improvement in the lesions and 
negative sputum examination results. 
DISCUSSION
Back pain in AS is defi  ned as slowly progressive pain worse-
ning during rest, which improves during exercise, and 
lasts ≥ 3 months. It is considered to be the main symptom 
of inflammatory spinal disorders and is a key factor for 
early diagnosis.
1) Th   e clinical characteristics of AS can be 
subcategorized into articular and extraarticular symptoms. 
The articular symptoms include inflammatory back 
pain that progresses slowly and sacroilitis. Opisthotonos 
appears in the later stages and the peripheral joints in-
volved are usually the hip joint and knee joint with rare 
cases of the upper and lower extremity joints. The extra-
articular symptoms include acute anterior uveitis, 
cardiovascular symptoms, pulmonary involvement, in-
flammatory intestinal diseases, and osteoporosis. The 
main symptoms complained of by the patients in the fi  rst 
medical examination in this study were back pain in most 
cases and hip joint pain or knee joint pain in some cases. 
With regard to the peripheral joint involvement, there 
were 3 cases (27%) of hip joint or knee joint involvement. 
The clinical course of AS vary and include episodes of 
natural improvement and worsening, which results in 
mild disability in most cases but severe disability in some 
cases.
6) 
Th   us far, the treatment of AS has focused on dealing 
with the symptoms using NSAIDs and kinesitherapy. 
However, with the recent introduction of anti-TNF a  gents, 
such as etanercept and infl  iximab, a new chapter has been 
opened for the treatment of rheumatoid arthritis and AS, 
and there are many reports on their efficacy and safety 
based on randomized control  led studies.
4,5,7) Still, there 
is some controversy regarding suitable candidates for 
treatment, time of the injection, treatment duration and its 
effi   cacy in preventing the progress of rheumatoid arthritis 
and AS.
4,7-9) The US FDA reported in March 2008 that 
etanercept treatments led to serious infections requiring 
hospital stays or caused life-threatening conditions. Th  ey 
recommended that patients be monitored for symptoms 
or signs of infection during treatment.
10) Complications, 
such as tumors and autoimmune diseases, can also occur. 
In addition, it is important to select suitable candidates 
who would be expected to be responsive to the treatments 
because these anti-TNF agents are expensive. 
Clinicians using anti-TNF agents should be well 
aware of the possible side effects and perform precise 
assessments. One of the most important side effects is 
an increased risk of severe infections, and the anti-TNF 
agents should be used with extreme care in patients 
vulnerable to infections, such as diabetics. Patients given 
anti-TNF treatments should be provided with explanations 
on the risk of infections and admonished not to ignore 
the signs of a serious infection and reported them to their 
doctors as soon as possible. In addition, when a surgical 
procedure is required in a patient under an anti-TNF 
treatment, careful caution should be taken before and aft  er 
surgery, and the agent should be re-administered after 
recovery of the surgical site is obtained.
11) In this study, 
the patient with previous total hip arthroplasty reported a 
superfi  cial infection in the left   inguinal area 3 weeks aft  er 
its occurrence. Accordingly, early treatment was delayed 
and revision surgery is under consideration because a 
deep infection around the implant is suspected. Th  erefore, 
it is believed that a more careful follow-up and treatment 
are needed for patients with implants. 
Local fl  are and swelling associated with a subcuta-
neous injection of the agents are the most common side 
eff  ects, which usually improve within 24 hours. Th  ese  con-
ditions can be treated with antihistamine without the need 
to stop the anti-TNF agents because they have no impact 
on the effi   cacy of the agents used.
5) In this study, a case of 
minor pruritus was observed aft  er the injection. 
Th   e treatment results of AS can be assessed in terms 
of the quality of life using the Ankylosing Spondylitis 
Quality of Life Questionnaire, of the disease activity using 
the BASDAI, and of the functions and joint stiff  ness using 
the Bath Ankylosing Spondylitis Functional Index and 
Bath Ankylosing Spondylitis Metrology Index. In this 
study, the BASDAI was used to assess the disease activity 
in patients under the etanercept treatment and signifi  cant 
improvement in the patients’ conditions was observed 
aft  er 12 weeks of the injection. With regard to the decrease 
in the BASDAI in patients subdivided according to the 
illness duration, remarkable improvement was found in all 
patients. 
The ESR is a nonspecific test that is determined 
by the concentration of plasma proteins, particularly fi-
brinogen, and is affected by other factors, such as age, 33
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gender, and time of measurement. In contrast, the CRP 
level increases in response to tissue damage, rises con-
tinuously due to chronic infl  ammation, and is less aff  ected 
by other factors. In this study, changes in the ESR and 
CRP levels were observed to assess the improvement in 
chronic inflammation. The ESR decreased drastically at 
3 months since the injection and by 64% at 12 months 
since the injection compared to the value measured 
before the injection. Th   e CRP also decreased the most at 
3 months since the injection and by 57% at 12 months 
since the injection. Each reduction ratio of the ESR and 
CRP at 12 months since the injection was analyzed, but 
there was no significant difference between the groups 
divided according to the illness duration. This suggests 
that the infl  ammatory response to the etanercept injection 
decreased the most at 3 months since the injection and 
continued to fall until 12 months since the injection. 
There are many reports on the prompt and prolonged 
effect of the biological agents.
2-5) However, there are still 
many unanswered questions: whether the long-term use 
of these biological agents can be effective in reducing 
infl  ammation; whether the use of such agents can result in 
radiological improvement; whether their efficacy can be 
maintained; and whether the injection should be stopped 
or continued based on certain standards. 
The etanercept injection resulted in a reduced in-
flammatory response and improvement in the BASDAI 
scores in patients with AS who were unresponsive to their 
previous treatments. It is believed that etanercept is eff  ect-
ive in blocking the progress of the disease and improving 
the symptoms in AS patients who are unresponsive to 
DMARDs, such as methotrexate and lefl  unomide, despite 
the risk of side effects and complica  tions. However, 
considering the risk of infection during injection, it 
should be used with extreme care in patients vulnerable 
to infection. Patients under etanercept treatment should 
be monitored closely and alerted to the risk of infection. 
Future studies should focus on determining the long-term 
efficacy of biological agents and the standards to which 
treatment decisions, such as continuation/discontinuation 
of the treatment and injection time, are based using a long-
term follow-up and an examination of various parameters.